Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

NCT ID: NCT05552495

Last Updated: 2023-01-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-23
• Study Completion Date: 2022-12-12

Brief Summary

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-386 in healthy volunteers under fasting conditions.

Detailed Description

To 30 healthy subjects, following treatments are administered dosing in each period and wash-out period is a minimum of 14 days Pharmacokinetic blood samples are collected up to 72hrs. The pharmacokinetic characteristics and safety are assessed.

Conditions

Hypertension and Dyslipidemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Reference-Test1-Test2

Group Type: EXPERIMENTAL

CKD-386(4) F1

Intervention Type: DRUG

1 Tablet

CKD-386(4) F2

Intervention Type: DRUG

1 Tablet

D013, D326, D337

Intervention Type: DRUG

D013 1 Tablet, D326 1Tablet, D337 1 Tablet

Reference-Test2-Test1

Group Type: EXPERIMENTAL

CKD-386(4) F1

Intervention Type: DRUG

1 Tablet

CKD-386(4) F2

Intervention Type: DRUG

1 Tablet

D013, D326, D337

Intervention Type: DRUG

D013 1 Tablet, D326 1Tablet, D337 1 Tablet

Test1-Reference-Test2

Group Type: EXPERIMENTAL

CKD-386(4) F1

Intervention Type: DRUG

1 Tablet

CKD-386(4) F2

Intervention Type: DRUG

1 Tablet

D013, D326, D337

Intervention Type: DRUG

D013 1 Tablet, D326 1Tablet, D337 1 Tablet

Test1-Test2-Reference

Group Type: EXPERIMENTAL

CKD-386(4) F1

Intervention Type: DRUG

1 Tablet

CKD-386(4) F2

Intervention Type: DRUG

1 Tablet

D013, D326, D337

Intervention Type: DRUG

D013 1 Tablet, D326 1Tablet, D337 1 Tablet

Test2-Reference-Test1

Group Type: EXPERIMENTAL

CKD-386(4) F1

Intervention Type: DRUG

1 Tablet

CKD-386(4) F2

Intervention Type: DRUG

1 Tablet

D013, D326, D337

Intervention Type: DRUG

D013 1 Tablet, D326 1Tablet, D337 1 Tablet

Test2-Test1-Reference

Group Type: EXPERIMENTAL

CKD-386(4) F1

Intervention Type: DRUG

1 Tablet

CKD-386(4) F2

Intervention Type: DRUG

1 Tablet

D013, D326, D337

Intervention Type: DRUG

D013 1 Tablet, D326 1Tablet, D337 1 Tablet

Interventions

CKD-386(4) F1

1 Tablet

Intervention Type: DRUG

CKD-386(4) F2

1 Tablet

Intervention Type: DRUG

D013, D326, D337

D013 1 Tablet, D326 1Tablet, D337 1 Tablet

Intervention Type: DRUG

Other Intervention Names

Test1; Test2; Reference

Eligibility Criteria

Inclusion Criteria

1. Healthy adults volunteers aged ≥19 years

2. Individuals who had 18 kg/m2 ≤ Body Mass Index(BMI) < 30 kg/m2 and total body weight ≥ 55 kg BMI = Weight(kg)/ Height(m)2

3. Following vital signs results at screening

• Systolic blood pressure: 90 mmHg to 139 mmHg
• Diastolic blood pressure: 60 mmHg to 89 mmHg

4. Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination

5. Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, serology, urology etc.) and ECG etc. performed

6. Individuals who agreed proper contraception during the study and did consent to not donation of sperm or eggs 14 days after the last dose of study drug

7. Individuals who signed an informed consent form after being fully informed of the study prior to participation, including the objective and content

Exclusion Criteria

1. Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within the 6 months prior to the first administration of investigational drugs

2. Those who have used drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first dosing date, or who have used drugs that may interfere with this study within 10 days before the first dosing day (However, clinical investigational drugs) Participation is possible in consideration of pharmacokinetic and pharmacodynamic characteristics such as interaction with concomitant drugs and half-life of concomitant drugs)

3. Individuals who donated whole blood within the 8 weeks, or blood components within 4 weeks or had a blood transfusion within 4 weeks prior to the first administration of investigational drugs

4. Individuals who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery

5. Individuals who meet the following condition with 1 month of the first administration of investigational drugs

• Alcohol: Man-21 glasses/week, Woman-14 glasses/week (1 glass = soju 50mL or liquor 30mL or beer 250mL)
• Smoking: 20 cigarettes/day

6. Patients with the following diseases

• Patients with hypersensitivity to the main constituents or components of the investigational drug
• Severe hepatic impairment, biliary atresia or cholestasis
• Patients with hereditary angioedema or with a history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor antagonists
• Diabetes mellitus
• Patients with moderate to severe renal impairment [glomerular filtration rate (eGFR) <60 mL / min / 1.73m^2]
• Renal vascular hypertension patients
• Patients with active liver disease, including unexplained persistent serum transaminase elevations or elevated serum transaminase elevations greater than three times the normal upper limit
• Patients with myopathy or have a history of family or genetic history of myopathy
• Hypothyroidism
• If you have a history of muscle toxicity for other HMG-CoA converting enzymes or fibrate class drugs

7. Individuals who have genetic problems such as galactose intolerance, Lap lactase deficiency, or glucose-galactose malabsorption

8. Those who are deemed insufficient to participate in this clinical study by investigators

9. Woman who are pregnant or breastfeeding

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jaewoo Kim, M.D.

Role: PRINCIPAL_INVESTIGATOR

Gwanak-gu, Seoul, South Korea, 08779

Locations

H+ Yangji Hospita

Seoul, , South Korea

Countries

South Korea

Other Identifiers

A83_09BE2219P

Identifier Type: -

Identifier Source: org_study_id